Methylpropyltryptamine

Methylpropyltryptamine
Clinical data
Other names	MPT; N-Methyl-N-propyltryptamine
Routes of; administration	Oral
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name N-[2-(1H-indol-3-yl)ethyl]-N-methylpropan-1-amine;
CAS Number	850032-72-3 ;
PubChem CID	74405270;
ChemSpider	96351249;
UNII	CWD3LY2N3Z;
Chemical and physical data
Formula	C14H20N2
Molar mass	216.328 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(C)CCC1=CNC2=C1C=CC=C2;
	InChI InChI=1S/C14H20N2/c1-3-9-16(2)10-8-12-11-15-14-7-5-4-6-13(12)14/h4-7,11,15H,3,8-10H2,1-2H3; Key:SZUNESAKJQIJAC-UHFFFAOYSA-N;

Methylpropyltryptamine (MPT), also known as N-methyl-N-propyltryptamine, is a psychedelic drug of the tryptamine family. It is a homologue of methylethyltryptamine (MET).^[1]

Use and effects

In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin described MPT's effects as being unknown and its dose as being greater than 50 mg orally.^[1]

Interactions

Chemistry

Detection

An analytical method for MPT's detection has been reported.^[2]

Crystal structure

In 2019, Chadeayne et al. published the crystal structure of MPT.^[3] The authors describe the structure as "...a single molecule in the asymmetric unit, with an indole group that demonstrates a mean deviation from planarity of 0.015 A°."

Analogues

Analogues of MPT include 4-HO-MPT, 5-MeO-MPT, methylethyltryptamine (MET), ethylpropyltryptamine (EPT), ethylisopropyltryptamine (EiPT), and dipropyltryptamine (DPT), among others.^[1]

Society and culture

Legal status

Canada

MPT is not a controlled substance in Canada as of 2025.^[4]

United States

MPT is not an explicitly controlled substance in the United States.^[5] However, it is an isomer of diethyltryptamine (DET), which is a schedule I controlled substance in this country, and so may be considered a controlled substance in the United States similarly.^[5]^[6]

References

1 2 3 4 Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
↑ Brandt SD, Freeman S, Fleet IA, Alder JF (September 2005). "Analytical chemistry of synthetic routes to psychoactive tryptamines. Part III. Characterisation of the Speeter and Anthony route to N,N-dialkylated tryptamines using CI-IT-MS-MS". The Analyst. 130 (9): 1258–1262. Bibcode:2005Ana...130.1258B. doi:10.1039/b504001a. PMID 16096671.
↑ Chadeayne AR, Golen JA, Manke DR (2019-07-28). "N -Methyl- N -propyltryptamine (MPT)". IUCrData. 4 (7) x190962. Bibcode:2019IUCrD...490962C. doi:10.1107/S2414314619009623. ISSN 2414-3146.
↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
1 2 Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
↑ Drug Enforcement Administration (3 December 2007). "Definition of "Positional Isomer" as It Pertains to the Control of Schedule I Controlled Substances". Federal Register.

External links

[TiHKAL-1] 1 2 3 4 Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.

[2] Brandt SD, Freeman S, Fleet IA, Alder JF (September 2005). "Analytical chemistry of synthetic routes to psychoactive tryptamines. Part III. Characterisation of the Speeter and Anthony route to N,N-dialkylated tryptamines using CI-IT-MS-MS". The Analyst. 130 (9): 1258–1262. Bibcode:2005Ana...130.1258B. doi:10.1039/b504001a. PMID 16096671.

[3] Chadeayne AR, Golen JA, Manke DR (2019-07-28). "N -Methyl- N -propyltryptamine (MPT)". IUCrData. 4 (7) x190962. Bibcode:2019IUCrD...490962C. doi:10.1107/S2414314619009623. ISSN 2414-3146.

[CDSA-4] "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.

[OrangeBook2026-5] 1 2 Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026

[DEA2007-6] Drug Enforcement Administration (3 December 2007). "Definition of "Positional Isomer" as It Pertains to the Control of Schedule I Controlled Substances". Federal Register.

[1]

[2]

[3]

[4]

[5]

[6]